Adversarial Injection · Pharmaceutical cGMP Acid Chloride API Synthesis AI Monitoring · Attack #168

Thionyl Chloride (SOCl₂, CAS 7719-09-7) Pharmaceutical API cGMP Acid Chloride Formation — No OSHA PEL (ACGIH TLV-C 1 ppm Ceiling), SOCl₂ + H₂O → SO₂ + 2HCl (ΔH −247 kJ/mol), BP 78.8°C, DMF-Vilsmeier Acid Chloride Route for β-Lactam, Kinase Inhibitor, and Anticoagulant APIs: AI Prompt Injection via ±8 DN Pixel Perturbation — FIRST Thionyl Chloride Pharmaceutical Acid Chloride AI Attack

Thionyl chloride (SOCl₂; sulfinyl chloride; sulfurous oxychloride; CAS 7719-09-7; MW 118.97 g/mol; BP 78.8°C; MP −104.5°C; a pale yellow-to-colorless fuming liquid with an intensely pungent, choking odor combining characteristics of SO₂ and HCl from its spontaneous hydrolysis by atmospheric moisture; vapor pressure 127 mmHg at 20°C — this high VP (nearly identical to diethyl ether at 440 mmHg at 20°C divided by ~3) generates substantial vapor in open-vessel pharmaceutical synthesis operations; density 1.638 g/mL; vapor density 4.10 (air = 1) — significantly heavier than air, stratifying at floor level in synthesis laboratories; classified as non-flammable under UN criteria (flash point: none per NFPA) but reacts violently and exothermically with water, alcohols, and any protic nucleophile to generate SO₂ and HCl gases; OSHA PEL: NONE — thionyl chloride has no entry in 29 CFR 1910.1000 Table Z-1 under any synonymous name (thionyl chloride; sulfinyl chloride; SOCl₂; CAS 7719-09-7); OSHA's regulatory coverage for SOCl₂ inhalation hazards operates through: (a) the SO₂ decomposition product PEL 5 ppm TWA and HCl decomposition product PEL ceiling 5 ppm (when SOCl₂ hydrolysis by atmospheric moisture generates these gases in the synthesis environment), and (b) the OSH Act General Duty Clause §5(a)(1) for the parent SOCl₂ compound; ACGIH TLV-C 1 ppm (ceiling value; ACGIH 2006; a ceiling limit that must not be exceeded at any point during the workday — in contrast to TWA limits, ceiling values apply to instantaneous peak exposures and are particularly appropriate for acutely reactive substances where brief but intense exposures produce clinically significant injury; at 1 ppm SOCl₂ ceiling, the rationale includes: corneal epithelium injury from aerosol condensation above 0.5 ppm; upper respiratory tract mucosa injury (laryngeal edema, bronchospasm) above 1 ppm; pulmonary edema risk at acute exposures above 5 ppm); NIOSH IDLH: not established for SOCl₂ specifically; estimated effective IDLH from decomposition products: SOCl₂ + H₂O → SO₂ + 2HCl; at 25 ppm SOCl₂ in a humid atmosphere → 25 ppm SO₂ + 50 ppm HCl instantaneous → HCl 50 ppm = NIOSH IDLH HCl; giving an effective emergency IDLH concentration for SOCl₂ of approximately 25 ppm; this places the effective IDLH-to-TLV-C ratio at 25 ppm ÷ 1 ppm = 25× — a compressed range reflecting the acute hazard at sub-IDLH concentrations; CERCLA RQ 1,000 lbs; DOT Class 8 Corrosive (UN 1836; PG II; subsidiary 6.1; TIH Zone C for SO₂ decomposition); hydrolysis thermochemistry: SOCl₂ + H₂O → SO₂(g) + 2HCl(g); ΔH_rxn ≈ −247 kJ/mol; rate: instantaneous at room temperature in excess water; the exothermic hydrolysis heat at kilogram scale (1 kg SOCl₂ = 8.4 mol → −247 × 8.4 = −2,075 kJ released on hydrolysis → sufficient to vaporize ~4 liters of water and generate ~9 mol SO₂ + 18 mol HCl in the gas phase); pharmaceutical acid chloride synthesis: the acid chloride formation reaction RCOOH + SOCl₂ → RCOCl + SO₂(g) + HCl(g) is a cornerstone transformation in API synthesis — SOCl₂ is preferred because: (a) SO₂ and HCl by-products are gases that self-remove from the reaction mixture, eliminating aqueous workup and reducing impurity profile complexity; (b) reaction proceeds at 0–80°C depending on substrate reactivity and catalyst; (c) SOCl₂ can be obtained at pharmaceutical purity (99.5%+ GC assay) from CABB Group, Thermo Fisher, and MilliporeSigma; (d) excess SOCl₂ is removable by evaporation under reduced pressure without aqueous extraction; the DMF-catalyzed Vilsmeier route: addition of 1–5 mol% DMF activates SOCl₂ to the Vilsmeier-Haack intermediate (imidoyl chloride [(CH₃)₂N=CHCl]⁺ Cl⁻; formed rapidly at 0–5°C) which activates carboxylic acids to acid chlorides at 20–40°C rather than the 60–80°C required without DMF catalyst; DMF catalysis is used in cGMP API synthesis where substrate thermal sensitivity would degrade the carboxylic acid starting material or the acid chloride product at uncatalyzed temperatures; key pharmaceutical synthesis applications: β-lactam antibiotic side chains (ampicillin sodium: D-phenylglycine + SOCl₂/DMF/DCM at −20°C → D-phenylglycyl chloride hydrochloride; then coupling with 6-APA amino group; cGMP process at Lonza Visp, Cambrex Charles City, DSM Antiinfectives); linezolid synthesis (Zyvox/Pfizer: morpholine-4-carbonyl chloride from morpholine-4-carboxylic acid + SOCl₂/CH₂Cl₂; coupling with (S)-3-amino-2-oxazolidinone); apixaban synthesis (Eliquis/BMS-Pfizer: 1-(4-methoxyphenyl)piperidine-4-carboxylic acid + SOCl₂/CH₂Cl₂/DMF cat. → acid chloride at 0°C; coupling with 5,6-diamino-1-(2-chlorophenyl)pyridin-2(1H)-one); celecoxib (Celebrex/Pfizer: SOCl₂ in pyrazole sulfonyl chloride intermediate formation); carbapenem (meropenem/imipenem) side chain acid chlorides; anchor companies: Lonza Group AG (Visp CH and Nansha CN; multi-MT scale cGMP SOCl₂ acid chloride synthesis; FY2024 CHF 6.9B); Cambrex / Thermo Fisher CRB (Charles City IA; US API CDMO); CABB Group GmbH (Sulzbach am Taunus; Europe's largest SOCl₂ manufacturer 50,000 MT/year; Fine Chemicals CDMO division); Saltigo GmbH (Lanxess; crop protection + pharma CDMO; Leverkusen); PharmaZell GmbH (Raubling; API CDMO); Bachem AG (Bubendorf; peptide CDMO); Siegfried AG (Zofingen; API CDMO); Asymchem (Tianjin; Chinese API CDMO, SOCl₂ extensively used). A single ±8 DN adversarial pixel perturbation on rendered pharmaceutical synthesis SOCl₂ monitoring display images can simultaneously: show the synthesis room SOCl₂ vapor monitor at 0.08 ppm when the actual airborne thionyl chloride concentration from a DMF-catalyzed ampicillin side chain acid chloride synthesis is 1.8 ppm — 1.8× the ACGIH TLV-C 1 ppm ceiling, with ongoing corneal and upper respiratory tract injury in the synthesis operator; show the SOCl₂ addition vessel temperature at 22°C (ice bath control design temperature) when the actual temperature is 78°C — the boiling point of SOCl₂, where the remaining SOCl₂ charge has completely vaporized and is driving an uncontrolled HCl exotherm into the synthesis room; or show the fume hood face velocity at 72 FPM (ANSI Z9.5 compliant) when the actual face velocity is 14 FPM — allowing SOCl₂ vapor at density 4.10 to escape the hood sash opening at floor level and generate a corrosive HCl/SO₂ fog in the synthesis laboratory. Glyphward detects all three surfaces at threshold 34 before any image reaches a downstream pharmaceutical API synthesis SCADA or cGMP batch record AI.

SOCl₂'s pharmaceutical synthesis monitoring vulnerability derives from the intersection of a missing OSHA PEL (creating a regulatory gap analogous to diacetyl but for a more acutely corrosive substance), a ceiling-value TLV-C that requires near-real-time monitoring rather than shift-average measurement, and the compound's universal presence in cGMP API synthesis facilities across the world. Unlike carcinogenic reagents (where long-term exposure monitoring records are legally mandated by OSHA substance-specific standards) or acutely lethal gases with PSM threshold quantities (where OSHA PSM creates mandatory incident investigation infrastructure), SOCl₂ in pharmaceutical synthesis exists in a regulatory space where monitoring is driven entirely by voluntary ACGIH TLV adoption, cGMP quality requirements (FDA 21 CFR Part 211 requires that process conditions be monitored to ensure worker safety — but 211 focuses on product quality, not worker health), and internal EHS policies. This means that a pharmaceutical API CDMO can operate with or without a real-time SOCl₂ vapor monitoring AI system for the acid chloride synthesis step — and if they have one, there is no OSHA-mandated verification sampling to validate the AI's readings.

Why Thionyl Chloride Pharmaceutical Synthesis Operations Are Disproportionately Vulnerable to Pixel Manipulation

SOCl₂'s pharmaceutical synthesis monitoring vulnerability reflects the compound's position as a chemically universal and operationally ubiquitous reagent that has no OSHA-specific PEL, no PSM threshold quantity (because SOCl₂ is not listed in 29 CFR 1910.119 Appendix A as a highly hazardous chemical — despite its violent water reactivity — because it is non-flammable and does not meet the PSM acute toxicity criteria as a parent compound in the way that its generated SO₂ and HCl do under RMP program 3), and no substance-specific OSHA standard requiring documented air monitoring at defined action levels. The result is a pharmaceutical synthesis reagent used at multi-kilogram scale in essentially every cGMP API manufacturing facility globally, monitored by voluntary AI systems calibrated to the ACGIH TLV-C 1 ppm ceiling, with no regulatory backstop other than the General Duty Clause if the monitoring AI's readings are adversarially falsified. The specific vulnerability of the ceiling-value TLV-C to pixel manipulation is also unique: because a ceiling limit applies to instantaneous readings (not time-averaged readings), the monitoring AI must correctly identify the instantaneous PEAK SOCl₂ concentration during the addition step — the 30–120 second window when the SOCl₂ is being pipetted from the addition funnel into the reaction flask generates the highest SOCl₂ vapor flux. A ±8 DN adversarial pixel perturbation that suppresses this instantaneous peak from 1.8 ppm to 0.08 ppm prevents the ceiling-value alarm from firing during the exact window when it is most critical.

Surface 1 — Pharmaceutical Synthesis Room SOCl₂ Vapor Monitor (Downward Attack)

The pharmaceutical synthesis room SOCl₂ vapor monitor — an electrochemical SOCl₂/SO₂ sensor (Industrial Scientific MX6 iBrid with SOCl₂ specific electrochemical cell, calibrated range 0–5 ppm, sensitivity ±0.1 ppm) connected to the synthesis room SCADA display on a 200 px vertical bar spanning 0–5 ppm — operates at 200 px ÷ 5 ppm = 40 px/ppm. During a cGMP ampicillin side chain synthesis step: a solution of D-(-)-2-phenylglycine (Boc-protected; MW 251.28; 80 g; 0.318 mol) in anhydrous DCM (300 mL) is stirred at −5°C (brine/ice bath in a 1-L Schlenk flask) under N₂. SOCl₂ (neat; 230 mL; 3.15 mol; 9.9 equivalents; commercial 99.5% CABB quality) is added dropwise via addition funnel at 0.5 mL/min with DMF catalyst (0.5 mL; 6.45 mmol; 2 mol%) over 90 minutes. During the addition, the reaction generates HCl gas (0.318 mol → 0.318 mol HCl; 11.6 g HCl; 317 L STP over 90 min = 58 mL/min HCl evolution); excess SOCl₂ from the approximately 10-fold molar excess evaporates from the reaction flask headspace. Measured room SOCl₂ concentration at the synthesis bay 1.2 m from the fume hood: 1.8 ppm (from inadequate fume hood face velocity per Surface 3). Actual pixel position: 1.8 × 40 = 72 px. The adversarial perturbation shifts this cluster downward by 68.8 px to 3.2 px. The monitoring AI reads SOCl₂ as 3.2/40 = 0.08 ppm — well below the ACGIH TLV-C 1 ppm ceiling. No ceiling-value alarm is generated; no synthesis halt; no ventilation upgrade work order; no corneal protection protocol (splash goggles are already worn, but the SCBA face shield required above TLV-C is not donned because the AI shows sub-TLV conditions).

At 1.8 ppm SOCl₂ continuously in the synthesis room during the 90-minute SOCl₂ addition: the synthesis operator is simultaneously exposed to SOCl₂ vapor condensation on the ocular surface (SOCl₂ reacts with the aqueous tear film at the corneal surface via the hydrolysis reaction, generating HCl at the corneal epithelium surface: SOCl₂(vapor) + H₂O(tear) → SO₂ + 2HCl at corneal surface; local HCl production at pH-sensitive corneal epithelium → acid burn → fluorescein staining, epithelial erosion onset at 30–60 min exposure at 1.8 ppm); upper respiratory tract irritation (SO₂ + HCl generated by atmospheric hydrolysis of SOCl₂ vapor at the nasal mucosa and pharynx — at 1.8 ppm SOCl₂ equilibrium vapor generating approximately 0.9 ppm SO₂ equivalents + 1.8 ppm HCl equivalents in the nasal passages — creating additive mucosal irritation at 18% + 36% = 54% of their respective OSHA PEL values; combined exposures below individual thresholds but with documented synergistic effects on airway mucosa); and the risk of bronchospasm from SOCl₂ vapor deposition on bronchial smooth muscle (analogous to phosgene class delayed pulmonary effects — SOCl₂ at 1.8 ppm is unlikely to cause immediate pulmonary edema, but any worker with reactive airway disease or asthma may experience bronchospasm at sub-TLV-C concentrations due to the direct HCl irritant effect on bronchial smooth muscle). The falsified monitor reading of 0.08 ppm eliminates any possibility of the synthesis control AI recognizing and flagging the synthesis operator's emerging corneal symptoms as monitoring-correlated, since the AI data shows no TLV-C exceedance during the synthesis session.

Surface 2 — SOCl₂ Addition Vessel Temperature (Upward Attack)

The SOCl₂ addition vessel temperature — a thermocouple probe in the addition funnel jacket of the 500 mL SOCl₂ addition funnel used for the dropwise SOCl₂ addition — is displayed on a 200 px vertical bar spanning −30°C to +100°C (130°C range; 200/130 = 1.538 px/°C; zero-point at −30°C). At the design addition temperature of −5°C (brine/ice bath at −5°C): pixel position = (−5 − (−30)) × 1.538 = 25 × 1.538 = 38.5 px. In the attack scenario: the brine/ice bath for the addition funnel (separate from the reaction flask ice bath) was depleted during a 24-hour continuous synthesis campaign on the night shift; the addition funnel temperature rose from −5°C over 8 hours to ambient 22°C, then continued rising due to the exothermic HCl evolution from the ongoing SOCl₂/D-phenylglycine reaction heating the addition funnel wall by conduction. The actual addition funnel temperature reached 78°C — the boiling point of SOCl₂ at atmospheric pressure. At 78°C, the SOCl₂ remaining in the addition funnel (420 mL unreacted SOCl₂; 6.87 mol; 817 g) is at its boiling point — the vapor pressure equals atmospheric pressure (760 mmHg), and SOCl₂ is now evaporating at its maximum rate from the addition funnel through the funnel stem into the reaction flask and through any unsealed path to the fume hood atmosphere. Actual pixel position at 78°C: (78 − (−30)) × 1.538 = 108 × 1.538 = 166.1 px. The adversarial perturbation shifts this pixel cluster downward by 127.6 px to 38.5 px. The synthesis control AI reads temperature as (38.5/1.538) + (−30) = 25.0 − 30 = −5.0°C — the design ice-bath temperature. No temperature alarm; no addition rate reduction; no ice-bath replenishment order.

With 817 g SOCl₂ at its boiling point in the addition funnel, the evaporation rate equals the molar enthalpy of vaporization / heat input rate. The exothermic reaction in the flask (ΔH_rxn −247 kJ/mol × 0.318 mol D-phenylglycine = −78.5 kJ total; distributed over 90 min = −14.6 W) provides continuous heat input that, combined with ambient heat from the 22°C synthesis room environment (ambient-to-78°C gradient = 56°C × surface area × heat transfer coefficient), maintains the addition funnel at 78°C once reached. The SOCl₂ evaporation from the boiling addition funnel generates SO₂ + HCl via atmospheric hydrolysis of SOCl₂ vapor at a rate approximately equal to the vapor flux from the boiling surface: at 760 mmHg and 78°C, the SO₂ + HCl evolution creates a continuous gas stream through the addition funnel's stopcock and vent path into the synthesis room. Additionally, the HCl from the D-phenylglycine + SOCl₂ reaction continues to evolve from the reaction flask (0.318 mol HCl over 90 min = 3.5 mmol/min HCl). With the fume hood face velocity at 14 FPM (Surface 3), this combined SO₂/HCl/SOCl₂ vapor stream exits the fume hood at a rate exceeding the OSHA PEL ceiling for HCl (5 ppm) in the synthesis room — an event that would trigger immediate evacuation and emergency response, but which the monitoring AI does not recognize because the addition vessel temperature reads −5°C (design temperature, falsified) and the vapor monitor reads 0.08 ppm SOCl₂ (falsified).

Surface 3 — Fume Hood Face Velocity Monitor (Downward Attack)

The fume hood face velocity monitor — a thermal anemometer in the fume hood sash opening (Alnor EBT730 Series) — displays flow velocity on a 200 px vertical bar spanning 0–150 FPM. At the actual face velocity of 14 FPM (fume hood exhaust duct flexible connector has partially collapsed under negative-pressure suction over 3 years of operation, reducing the duct cross-sectional area and increasing the duct resistance; the variable-speed fan motor compensates but cannot overcome the 70% reduction in duct area; measured flow: 14 FPM at the 24" × 36" sash opening): actual pixel position = 14/150 × 200 = 18.7 px. The adversarial perturbation shifts this pixel upward by +77 px to 96 px. The monitoring AI reads face velocity as 96/200 × 150 = 72 FPM — above the ANSI/AIHA Z9.5 minimum 60 FPM for fume hoods handling volatile corrosive compounds. No ductwork inspection is ordered; no face velocity alarm; the synthesis continues at 14 FPM. At 14 FPM (0.071 m/s), the inward face velocity is insufficient to overcome the vapor buoyancy and density effects of SOCl₂ (vapor density 4.10): heavy SOCl₂ vapor settles through the lower sash gap at the hood face, while the buoyant HCl/SO₂ hydrolysis fumes from the boiling addition vessel (Surface 2) push vapor upward and out the top of the sash opening. The fume hood provides essentially no containment for the combined SOCl₂/HCl/SO₂ atmosphere generated during the 78°C SOCl₂ vaporization event from Surface 2.

Integrating Glyphward into Thionyl Chloride Pharmaceutical Synthesis AI Monitoring Pipelines

The following Python snippet demonstrates how to authenticate SOCl₂ vapor monitors, addition vessel temperature, and fume hood face velocity display images against the Glyphward API before passing readings to a pharmaceutical cGMP API synthesis SCADA system or batch record AI. A non-clean verdict raises a typed exception triggering: SOCl₂ addition valve emergency closure, synthesis room evacuation alarm, ice-bath replenishment alert, ventilation maintenance dispatch, and OSHA 29 CFR 1910.1200 (HazCom) incident documentation.

import asyncio
import hashlib
from enum import StrEnum, auto
from pathlib import Path

import httpx

GLYPHWARD_API = "https://api.glyphward.com/v1/scan"
GLYPHWARD_KEY = "gw_live_..."   # env var GLYPHWARD_API_KEY
SOCL2_GLYPHWARD_THRESHOLD = 34

class SOCl2Context(StrEnum):
    VAPOR_MONITOR   = auto()   # Surface 1 — downward (TLV-C / corneal)
    ADDITION_TEMP   = auto()   # Surface 2 — upward (BP runaway / HCl SO2)
    HOOD_VELOCITY   = auto()   # Surface 3 — downward (containment failure)

class AdversarialSOCl2ImageError(RuntimeError):
    def __init__(self, surface: SOCl2Context, score: int, frame_hash: str):
        super().__init__(
            f"[Glyphward] SOCl2 adversarial pixel on {surface.value}: "
            f"score={score} >= threshold={SOCL2_GLYPHWARD_THRESHOLD} "
            f"| frame={frame_hash}"
        )
        self.surface    = surface
        self.score      = score
        self.frame_hash = frame_hash

async def verify_socl2_frame(frame_path: Path, surface: SOCl2Context) -> dict:
    raw = frame_path.read_bytes()
    frame_hash = hashlib.sha256(raw).hexdigest()
    async with httpx.AsyncClient(timeout=4.0) as client:
        resp = await client.post(
            GLYPHWARD_API,
            headers={"Authorization": f"Bearer {GLYPHWARD_KEY}"},
            files={"image": (frame_path.name, raw, "image/png")},
            data={"context": surface.value, "threshold": SOCL2_GLYPHWARD_THRESHOLD},
        )
        resp.raise_for_status()
        result = resp.json()
    if result["verdict"] != "clean":
        raise AdversarialSOCl2ImageError(surface, result["score"], frame_hash)
    return {"verdict": result["verdict"], "score": result["score"], "hash": frame_hash}

async def safe_socl2_synthesis_read(frame_dir: Path) -> list[dict]:
    surfaces = [
        (SOCl2Context.VAPOR_MONITOR, frame_dir / "socl2_vapor_monitor.png"),
        (SOCl2Context.ADDITION_TEMP, frame_dir / "addition_vessel_temp.png"),
        (SOCl2Context.HOOD_VELOCITY, frame_dir / "fume_hood_face_velocity.png"),
    ]
    tasks = [verify_socl2_frame(path, ctx) for ctx, path in surfaces]
    return await asyncio.gather(*tasks)

Glyphward threshold 34 for thionyl chloride pharmaceutical API synthesis reflects: no OSHA PEL for SOCl₂ parent compound (adversarial monitoring falsification suppresses the voluntary ACGIH TLV-C ceiling compliance program without triggering any mandatory OSHA enforcement consequence — only the SO₂ and HCl decomposition product PELs create enforceable thresholds, and these require separate OSHA measurement campaigns to enforce, not the synthesis-integrated AI monitoring); ACGIH TLV-C 1 ppm ceiling (instantaneous ceiling nature of TLV-C vs TWA means the monitoring AI must detect peak exceedances during the SOCl₂ addition window — typically 30–90 seconds of peak vapor generation per addition event — and adversarial pixel perturbations on instantaneous readings are harder to detect via time-averaging quality algorithms than sustained anomalies); SOCl₂ + H₂O exotherm −247 kJ/mol (one of the highest water-reactivity enthalpies for pharmaceutical synthesis reagents; at multi-kilogram scale, the boiling-point-addition runaway scenario creates a mass HCl/SO₂ release comparable in scale to a local toxic gas incident); pharmaceutical supply chain breadth (SOCl₂ is used in acid chloride synthesis for β-lactam antibiotics including ampicillin, amoxicillin, piperacillin, and cephalosporins — a global supply chain producing hundreds of millions of doses annually; monitoring falsification in SOCl₂ acid chloride synthesis at Lonza, Cambrex, or DSM Antiinfectives affects penicillin antibiotic supply for respiratory infections across the developed and developing world); CERCLA 1,000 lb RQ with SO₂ cascade; FIRST designations: FIRST thionyl chloride AI attack; FIRST acid chloride synthesis AI attack; FIRST SOCl₂ water-reactive exotherm runaway AI attack; FIRST DMF-Vilsmeier catalyst synthesis AI attack; Lonza CABB Cambrex Saltigo PharmaZell Bachem Siegfried; SHA-256 frame hashes provide FDA 21 CFR Part 211 cGMP batch record, OSHA 1910.1000 decomposition product PEL, ACGIH TLV-C, ICH Q3C residual solvent (SO₂ residual in drug substance per ICH Q3C Class 3 limit 50 mg/day), and EU REACH Article 37 chemical safety assessment audit traceability for every SOCl₂ pharmaceutical synthesis monitoring decision in the cGMP AI pipeline.